Summary
358.77 1.05(0.29%)09/27/2024
United Therapeutics Corp (UTHR)
United Therapeutics Corp (UTHR)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 0.25 | 1.70 | 2.74 | 13.19 | 47.47 | 54.33 | 343.80 | 5,787.46 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 358.77 | |
| Open | 359.82 | |
| High | 360.79 | |
| Low | 355.05 | |
| Volume | 166,232 | |
| Change | 0.89 | |
| Change % | 0.25 | |
| Avg Volume (20 Days) | 293,966 | |
| Volume/Avg Volume (20 Days) Ratio | 0.57 | |
| 52 Week Range | 208.62 - 366.08 | |
| Price vs 52 Week High | -2.00% | |
| Price vs 52 Week Low | 71.97% | |
| Range | -0.29 | |
| Gap Up/Down | -2.64 | |
Fundamentals | ||
| Market Capitalization (Mln) | 15,915 | |
| EBIDTA | 1,239,200,000 | |
| PE Ratio | 11.9541 | |
| PEG Ratio | 2.4897 | |
| WallStreet Target Price | 291.87 | |
| Book Value | 127.2260 | |
| Earnings Per Share | 19.8200 | |
| EPS Estimate Current Quarter | 4.1900 | |
| EPS Estimate Next Quarter | 5.3000 | |
| EPS Estimate Current Year | 23.9500 | |
| EPS Estimate Next Year | 24.6000 | |
| Diluted EPS (TTM) | 19.8200 | |
| Revenues | ||
| Profit Marging | 0.4231 | |
| Operating Marging (TTM) | 0.4249 | |
| Return on asset (TTM) | 0.1122 | |
| Return on equity (TTM) | 0.1827 | |
| Revenue TTM | 2,327,500,032 | |
| Revenue per share TTM | 49.7330 | |
| Quarterly Revenue Growth (YOY) | 0.2510 | |
| Quarterly Earnings Growth (YOY) | 0.6260 | |
| Gross Profit (TTM) | 1,784,700,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 11.9541 | |
| Forward PE | 10.5263 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 1.8632 | |
| Revenue Enterprise Value | 3.8053 | |
| EBITDA Enterprise Value | 6.3866 | |
| Shares | ||
| Shares Outstanding | 47,058,500 | |
| Shares Float | 43,372,449 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 1.72 | |
| Institutions (%) | 97.01 | |
09/24 07:00 EST - businesswire.com
United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the CHEST 2024 Annual Meeting
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that five presentations and one poster across its commercial and development portfolio will be presented at the CHEST 2024 Annual Meeting hosted by the American College of Chest Physicians taking place October 6-9, 2024, in Boston. United Therapeutics will sponsor the Tyvaso DPI®: Clinical Pearls and Drug-Device Characteristics Symposi.
United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the CHEST 2024 Annual Meeting
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that five presentations and one poster across its commercial and development portfolio will be presented at the CHEST 2024 Annual Meeting hosted by the American College of Chest Physicians taking place October 6-9, 2024, in Boston. United Therapeutics will sponsor the Tyvaso DPI®: Clinical Pearls and Drug-Device Characteristics Symposi.
08/30 12:36 EST - zacks.com
United Therapeutics (UTHR) Up 9.9% Since Last Earnings Report: Can It Continue?
United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock?
United Therapeutics (UTHR) Up 9.9% Since Last Earnings Report: Can It Continue?
United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock?
08/30 12:02 EST - fxempire.com
United Therapeutics Shares Thrive
Revenue growth and a recent regulatory win are driving shares of United Therapeutics Corporation (UTHR) upward.
United Therapeutics Shares Thrive
Revenue growth and a recent regulatory win are driving shares of United Therapeutics Corporation (UTHR) upward.
08/19 22:00 EST - seekingalpha.com
United Therapeutics: Economics Support Compounding Ability
United Therapeutics Corporation remains a buy with strong growth potential and high returns on invested capital. Q2 FY'24 earnings show continued growth in sales and earnings, with upsides in its Tyvaso segment. The company has started share buybacks and is on track to reach a $3 billion revenue run rate by FY'25, supporting a valuation of $400/share.
United Therapeutics: Economics Support Compounding Ability
United Therapeutics Corporation remains a buy with strong growth potential and high returns on invested capital. Q2 FY'24 earnings show continued growth in sales and earnings, with upsides in its Tyvaso segment. The company has started share buybacks and is on track to reach a $3 billion revenue run rate by FY'25, supporting a valuation of $400/share.
08/07 17:41 EST - investors.com
Stock Market Fades Badly As Dow Jones Index Turns Back At This Critical Level
The stock market's bearish reversal left its rebound in doubt but a rally attempt remains in play.
Stock Market Fades Badly As Dow Jones Index Turns Back At This Critical Level
The stock market's bearish reversal left its rebound in doubt but a rally attempt remains in play.
08/04 13:33 EST - investorplace.com
3 Biotech Stocks on Track for 50% Returns (or More) by 2028
The biotech industry, often recognized for its rapid innovation, can set investors up for outsized returns in the stock market. However, not all biotech companies have the capability of doing so.
3 Biotech Stocks on Track for 50% Returns (or More) by 2028
The biotech industry, often recognized for its rapid innovation, can set investors up for outsized returns in the stock market. However, not all biotech companies have the capability of doing so.
08/02 13:01 EST - zacks.com
United Therapeutics (UTHR) is a Great Momentum Stock: Should You Buy?
Does United Therapeutics (UTHR) have what it takes to be a top stock pick for momentum investors? Let's find out.
United Therapeutics (UTHR) is a Great Momentum Stock: Should You Buy?
Does United Therapeutics (UTHR) have what it takes to be a top stock pick for momentum investors? Let's find out.
08/02 12:46 EST - zacks.com
UTHR or ZTS: Which Is the Better Value Stock Right Now?
Investors with an interest in Medical - Drugs stocks have likely encountered both United Therapeutics (UTHR) and Zoetis (ZTS). But which of these two stocks presents investors with the better value opportunity right now?
UTHR or ZTS: Which Is the Better Value Stock Right Now?
Investors with an interest in Medical - Drugs stocks have likely encountered both United Therapeutics (UTHR) and Zoetis (ZTS). But which of these two stocks presents investors with the better value opportunity right now?
08/02 10:46 EST - zacks.com
Here's Why United Therapeutics (UTHR) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why United Therapeutics (UTHR) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
07/31 13:46 EST - zacks.com
3 Reasons Why Growth Investors Shouldn't Overlook United Therapeutics (UTHR)
United Therapeutics (UTHR) could produce exceptional returns because of its solid growth attributes.
3 Reasons Why Growth Investors Shouldn't Overlook United Therapeutics (UTHR)
United Therapeutics (UTHR) could produce exceptional returns because of its solid growth attributes.
07/31 11:28 EST - seekingalpha.com
United Therapeutics Corporation (UTHR) Q2 2024 Earnings Call Transcript
United Therapeutics Corporation (NASDAQ:UTHR ) Q2 2024 Earnings Conference Call July 31, 2024 9:00 AM ET Company Participants Dewey Steadman - Head of Investor Relations Martine Rothblatt - Chairperson & Chief Executive Officer Michael Benkowitz - President & Chief Operating Officer James Edgemond - Chief Financial Officer & Treasurer Leigh Peterson - Executive Vice President-Product Development & Xenotransplantation Conference Call Participants Roanna Ruiz - Leerink Partners Jessica Fye - JPMorgan Ash Verma - UBS Joseph Thome - TD Cowen Andreas Argyrides – Oppenheimer Operator Good morning, everyone and welcome to the United Therapeutics Corporation Second Quarter 2024 Earnings Webcast. My name is Cole and I will be your conference operator today.
United Therapeutics Corporation (UTHR) Q2 2024 Earnings Call Transcript
United Therapeutics Corporation (NASDAQ:UTHR ) Q2 2024 Earnings Conference Call July 31, 2024 9:00 AM ET Company Participants Dewey Steadman - Head of Investor Relations Martine Rothblatt - Chairperson & Chief Executive Officer Michael Benkowitz - President & Chief Operating Officer James Edgemond - Chief Financial Officer & Treasurer Leigh Peterson - Executive Vice President-Product Development & Xenotransplantation Conference Call Participants Roanna Ruiz - Leerink Partners Jessica Fye - JPMorgan Ash Verma - UBS Joseph Thome - TD Cowen Andreas Argyrides – Oppenheimer Operator Good morning, everyone and welcome to the United Therapeutics Corporation Second Quarter 2024 Earnings Webcast. My name is Cole and I will be your conference operator today.
07/31 10:56 EST - zacks.com
United Therapeutics (UTHR) Q2 Earnings Lag, Sales Top Estimates
United Therapeutics (UTHR) reports mixed second-quarter 2024 results. Tyvaso sales continue to drive the company's top line.
United Therapeutics (UTHR) Q2 Earnings Lag, Sales Top Estimates
United Therapeutics (UTHR) reports mixed second-quarter 2024 results. Tyvaso sales continue to drive the company's top line.
07/31 10:50 EST - zacks.com
Here's Why United Therapeutics (UTHR) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's Why United Therapeutics (UTHR) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
07/31 10:36 EST - zacks.com
United Therapeutics (UTHR) Reports Q2 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for United Therapeutics (UTHR) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
United Therapeutics (UTHR) Reports Q2 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for United Therapeutics (UTHR) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
07/31 08:41 EST - zacks.com
United Therapeutics (UTHR) Misses Q2 Earnings Estimates
United Therapeutics (UTHR) came out with quarterly earnings of $5.85 per share, missing the Zacks Consensus Estimate of $6.33 per share. This compares to earnings of $5.24 per share a year ago.
United Therapeutics (UTHR) Misses Q2 Earnings Estimates
United Therapeutics (UTHR) came out with quarterly earnings of $5.85 per share, missing the Zacks Consensus Estimate of $6.33 per share. This compares to earnings of $5.24 per share a year ago.
07/30 10:41 EST - zacks.com
Here's Why United Therapeutics (UTHR) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why United Therapeutics (UTHR) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
07/26 06:52 EST - investorplace.com
The 3 Best 3D Bioprinting Stocks to Buy Now
Investing in 3D bioprinting stocks is a highly speculative and specialized approach to the biotech industry in general. That's because it blends two relatively niche technologies to create a broader application that may be part of the future of surgery and medical treatments.
The 3 Best 3D Bioprinting Stocks to Buy Now
Investing in 3D bioprinting stocks is a highly speculative and specialized approach to the biotech industry in general. That's because it blends two relatively niche technologies to create a broader application that may be part of the future of surgery and medical treatments.
07/17 14:35 EST - schaeffersresearch.com
3 Biotech Stocks You Should Know About
In June, we profiled biotech exchange-traded fund (ETF) SPDR S&P Biotech ETF (XBI) amid a historically bullish month.
3 Biotech Stocks You Should Know About
In June, we profiled biotech exchange-traded fund (ETF) SPDR S&P Biotech ETF (XBI) amid a historically bullish month.
07/17 12:46 EST - zacks.com
UTHR vs. CTLT: Which Stock Is the Better Value Option?
Investors interested in Medical - Drugs stocks are likely familiar with United Therapeutics (UTHR) and Catalent (CTLT). But which of these two companies is the best option for those looking for undervalued stocks?
UTHR vs. CTLT: Which Stock Is the Better Value Option?
Investors interested in Medical - Drugs stocks are likely familiar with United Therapeutics (UTHR) and Catalent (CTLT). But which of these two companies is the best option for those looking for undervalued stocks?
07/17 10:51 EST - zacks.com
Why United Therapeutics (UTHR) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why United Therapeutics (UTHR) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.